Bluebird Bio Amends Merger Agreement with Carlyle

An update from Bluebird Bio ( (BLUE) ) is now available.

On May 13, 2025, bluebird bio, Inc. amended its merger agreement with Carlyle and SK Capital Partners, offering stockholders a choice between $3.00 per share plus a contingent value right (CVR) of $6.84 or a revised offer of $5.00 per share. The bluebird board of directors recommends stockholders tender their shares to avoid potential financial risks, including defaulting on loan agreements with Hercules Capital. The tender offer deadline has been extended to May 29, 2025, with approximately 2,281,724 shares already tendered.

The most recent analyst rating on (BLUE) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Bluebird Bio stock, see the BLUE Stock Forecast page.

Spark’s Take on BLUE Stock

According to Spark, TipRanks’ AI Analyst, BLUE is a Underperform.

Bluebird Bio’s stock is facing significant challenges primarily due to its weak financial performance, which is reflected in negative profitability and a precarious balance sheet. Technical indicators also suggest a bearish trend, while the negative P/E ratio highlights valuation difficulties. These factors combine to present a high-risk profile for the stock with limited near-term upside potential.

To see Spark’s full report on BLUE stock, click here.

More about Bluebird Bio

Founded in 2010, bluebird bio, Inc. is a leader in the gene therapy industry, focusing on severe genetic diseases. The company has achieved FDA approvals for three therapies and is known for its innovative solutions in gene therapy, particularly for conditions like sickle cell disease, ß-thalassemia, and cerebral adrenoleukodystrophy.

Average Trading Volume: 466,664

Technical Sentiment Signal: Strong Sell

Current Market Cap: $32.21M

See more data about BLUE stock on TipRanks’ Stock Analysis page.